Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Spesolimab - Boehringer Ingelheim

Next Previous
X
Search
Drug Profile

Spesolimab - Boehringer Ingelheim

Alternative Names: BI 655130; Spesolimab-sbzo; SPEVIGO

Latest Information Update: 09 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 36 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Generalised pustular psoriasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Generalised pustular psoriasis
  • Phase II/III Hidradenitis suppurativa; Netherton Syndrome; Ulcerative colitis
  • Phase II Crohn's disease; Palmoplantar pustulosis; Pyoderma gangrenosum
  • Discontinued Atopic dermatitis

Most Recent Events

  • 03 Oct 2024 Boehringer Ingelheim plans a phase III trial for Pyoderma Gangrenosum (IV, infusion) in January 2025 (NCT06624670)
  • 30 Jul 2024 Boehringer Ingelheim initiates enrolment in a phase I trial (In volunteers) in Belgium (SC) (NCT06520514)
  • 30 Jul 2024 CHMP of the EMA recommends approval of a new and expanded indication of spesolimab for the prevention and treatment of generalized pustular psoriasis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top